Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2240-2244

  Jabs, Douglas A ^a,b   Enger, Cheryl ^a   Forman, Michael ^a   Dunn, J P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD CULTURE; CYTOMEGALOVIRUS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; TREATMENT OUTCOME; URINE CULTURE;

EID: 0031691452     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2240     Document Type: Article

References (19)

1. Baldanti, F., M. R. Underwood, S. C. Stanat, K. K. Biron, S. Chou, A. Sarasini, E. Silini, and G. Gerna. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1390-1395.
2. Cherrington, J. Personal communication.
3. Cherrington, J. M., R. Miner, M. J. Hitchcock, J. P. Lalezari, and W. L. Drew. 1996. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug. J. Infect. Dis. 173:987-992.
4. Chou, S., S. Guentzel, K. R. Michels, R. C. Miner, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172:239-242.
5. Dankner, W. M., D. Scholl, S. C. Stanat, M. Martin, R. L. Sonke, and S. A. Spector. 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28:293-298.
6. Drew, W. L., R. C. Miner, D. F. Busch, S. E. Follansbee, J. Gullett, S. G. Mehalko, S. M. Gordon, W. F. Owen, Jr., T. R. Matthews, W. C. Buhles, and B. DeArmond. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719.
7. Drew, W. L., R. C. Miner, and E. Saleh. 1993. Antiviral susceptibility of cytomegalovirus: criteria for detecting resistance to antivirals. Clin. Diagn. Virol. 1:179-185.
8. Dunn, J. P., M. W. MacCumber, M. S. Forman, P. Charache, L. Apuzzo, and D. A. Jabs. 1995. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am. J. Ophthalmol. 119:587-596
9. Enger, C., D. A. Jabs, J. P. Dunn, M. S. Forman, N. M. Bressler, J. B. Margolick, P. Charache, and the CRVR Research Group. 1997. Viral resistance and CMV retinitis: design and methods of a prospective study. Ophthalmic Epidemiol. 4:41-48.
10. Hoover, D. R., Y. Peng, A. Saah, R. Semba, R. R. Detels, C. R. Rinaldo, Jr., and J. P. Phair. 1996. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch. Ophthalmol. 114:821-827.
11. Jabs, D. A. 1995. Ocular manifestations of HIV infection. Trans. Am. Ophthalmol. Soc. 93:623-683.
12. Jabs, D. A., J. P. Dunn, C. Enger, M. Forman, N. Bressler, and P. Charache for the Cytomegalovirus Retinitis and Viral Resistance Study Group. 1996. Cytomegalovirus retinitis and viral resistance: prevalence of resistance at diagnosis, 1994. Arch. Ophthalmol. 114:809-814.
13. Jabs, D. A., C. Enger, and J. G. Bartlett. 1989. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch. Ophthalmol. 107:75-80.
14. Jabs, D. A., C. Enger, J. P. Dunn, and M. Forman for the Cytomegalovirus Retinitis and Viral Resistance Study Group. 1998. Cytomegalovirus resistance and viral resistance. 4. Ganciclovir resistance. J. Infect. Dis. 177:770-773.
15. Leport, C., S. Puget, J. M. Pepin, S. Levy, C. Perronne, F. Brun-Vezinet, and J. L. Vilde. 1993. Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J. Infect. Dis. 168:1329-1330. (Letter.)
16. Palestine, A. G., M. A. Polis, M. D. De Smet, B. F. Baird, J. Falloon, J. A. Kovacs, R. T. Davey, J. J. Zurlo, K. M. Zunich, M. Davis, L. Hubbard, R. Brothers, F. L. Ferris, E. Chew, J. L. Davis, B. I. Rubin, S. D. Mellow, J. A. Metcalf, J. Manischewitz, J. R. Minor, R. B. Nussenblatt, H. Masur, and H. C. Lane. 1991. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann. Intern. Med. 115:665-673.
17. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
18. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. 1994. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophthalmology 101:1250-1261.
19. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. 1997. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. J. Infect. Dis. 176:50-58.